The reason we recommended involving specialist legal counsel at an early stage of a deal in the first part of this series is because there is always a risk the proposed deal may not work for some reason or, at least, does not work exactly as the parties originally envisaged.
According to many, the anticipated arrival of Humira biosimilars in the US next year has pushed AbbVie's drug to the precipice of the pharma industry’s biggest-ever patent cliff.
Potter Clarkson has maintained its position as one of the top four patent specialists in Europe, according to the latest Europe’s Leading Patent Law Firms report from the Financial Times.
The UK Government have released the Policy paper “British energy security strategy” with the aim of providing “secure, clean and affordable British energy for the long term.”
Vegans and vegetarians must consciously check the credentials of products during the purchasing process. Not only that, but consumers are increasingly seeking out brands which match their ethical and moral beliefs. This is perhaps most apparent in relation to the food and drink they consume.
In the previous part of this series we looked at three tips that will help you structure better deals with potential partners, collaborators or licensees. The first of those tips was to put a meaningful NDA in place before negotiations start so in this part we thought it may be useful to look at NDAs.